Article
The FDA has consolidated three existing areas within the Center for Drug Evaluation and Research to form the Office of Oncology Drug Products.
Enrollment goal met in phase 3 SOLAR-RECUR trial
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
FDA accepts sNDA for darolutamide plus ADT in mHSPC
Key updates from the AUA/ASRM male infertility guideline amendment
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
Dean Laganosky, M.D., named Urology Trailblazer for 2024